Controlling oxidative stress in non-alcoholic steatohepatitis (NASH)

Akinobu Takaki, Daisuke Kawai, Kazuhide Yamamoto

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Non-alcoholic steatohepatitis (NASH) is a severe form of non- alcoholic fatty liver disease (NAFLD), in which most patients exhibit non-progressive non-alcoholic fatty liver (NAFL) representing simple steatosis of the liver. Multiple hits, including genetic differences, fat accumulation, insulin resistance and intestinal microbiota changes, account for the progression NASH. NAFLD is strongly associated with obesity, which induces adipokine secretion, endoplasmic reticulum (ER) and oxidative stress at the cellular level, and induces hepatic steatosis, inflammation and fibrosis. Among these factors, oxidative stress is considered a key contributor to the progression from NAFL to NASH. Although several clinical trials have shown that anti-oxidative therapy with vitamin E can effectively control the effects of hepatitis in the short term, the long-term effects remains obscure. Several trials of long-term anti-oxidant protocols aimed at treating cerebrovascular diseases or cancer development have failed to demonstrate benefits. This might be attributed to the non-selective anti-oxidant properties or excessive anti- oxidative effects of these drugs. Molecular hydrogen has recently been identified as an effective antioxidant that specifically reduces cytotoxic reactive oxygen species (ROS). Several diseases associated with oxidative stress, such as ischemia reperfusion injury of brain or heart, Parkinson's disease, post-chemotherapeutic renal injury, or transplant rejection, are responsive to hydrogen. The progress of NASH and transition of NASH to hepatocellular carcinoma can be controlled using hydrogen-rich water in mouse models. Long-term clinical intervention is required to control this complex lifestyle-related disease.

Original languageEnglish
Title of host publicationOxidative Stress: Causes, Role in Diseases and Biological Effects
PublisherNova Science Publishers, Inc.
Pages139-176
Number of pages38
ISBN (Print)9781631175794, 9781631175787
Publication statusPublished - Apr 1 2014

Fingerprint

Oxidative stress
Fatty Liver
Oxidative Stress
Liver
Hydrogen
Oxidants
Transplants
Adipokines
Vitamin E
Cerebrovascular Disorders
Endoplasmic Reticulum Stress
Reactive Oxygen Species
Brain
Graft Rejection
Antioxidants
Reperfusion Injury
Fats
Insulin
Hepatitis
Parkinson Disease

Keywords

  • Non-alcoholic steatohepatitis
  • Oxidative stress

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Takaki, A., Kawai, D., & Yamamoto, K. (2014). Controlling oxidative stress in non-alcoholic steatohepatitis (NASH). In Oxidative Stress: Causes, Role in Diseases and Biological Effects (pp. 139-176). Nova Science Publishers, Inc..

Controlling oxidative stress in non-alcoholic steatohepatitis (NASH). / Takaki, Akinobu; Kawai, Daisuke; Yamamoto, Kazuhide.

Oxidative Stress: Causes, Role in Diseases and Biological Effects. Nova Science Publishers, Inc., 2014. p. 139-176.

Research output: Chapter in Book/Report/Conference proceedingChapter

Takaki, A, Kawai, D & Yamamoto, K 2014, Controlling oxidative stress in non-alcoholic steatohepatitis (NASH). in Oxidative Stress: Causes, Role in Diseases and Biological Effects. Nova Science Publishers, Inc., pp. 139-176.
Takaki A, Kawai D, Yamamoto K. Controlling oxidative stress in non-alcoholic steatohepatitis (NASH). In Oxidative Stress: Causes, Role in Diseases and Biological Effects. Nova Science Publishers, Inc. 2014. p. 139-176
Takaki, Akinobu ; Kawai, Daisuke ; Yamamoto, Kazuhide. / Controlling oxidative stress in non-alcoholic steatohepatitis (NASH). Oxidative Stress: Causes, Role in Diseases and Biological Effects. Nova Science Publishers, Inc., 2014. pp. 139-176
@inbook{9624057f69e7424d8e066ecd117e203e,
title = "Controlling oxidative stress in non-alcoholic steatohepatitis (NASH)",
abstract = "Non-alcoholic steatohepatitis (NASH) is a severe form of non- alcoholic fatty liver disease (NAFLD), in which most patients exhibit non-progressive non-alcoholic fatty liver (NAFL) representing simple steatosis of the liver. Multiple hits, including genetic differences, fat accumulation, insulin resistance and intestinal microbiota changes, account for the progression NASH. NAFLD is strongly associated with obesity, which induces adipokine secretion, endoplasmic reticulum (ER) and oxidative stress at the cellular level, and induces hepatic steatosis, inflammation and fibrosis. Among these factors, oxidative stress is considered a key contributor to the progression from NAFL to NASH. Although several clinical trials have shown that anti-oxidative therapy with vitamin E can effectively control the effects of hepatitis in the short term, the long-term effects remains obscure. Several trials of long-term anti-oxidant protocols aimed at treating cerebrovascular diseases or cancer development have failed to demonstrate benefits. This might be attributed to the non-selective anti-oxidant properties or excessive anti- oxidative effects of these drugs. Molecular hydrogen has recently been identified as an effective antioxidant that specifically reduces cytotoxic reactive oxygen species (ROS). Several diseases associated with oxidative stress, such as ischemia reperfusion injury of brain or heart, Parkinson's disease, post-chemotherapeutic renal injury, or transplant rejection, are responsive to hydrogen. The progress of NASH and transition of NASH to hepatocellular carcinoma can be controlled using hydrogen-rich water in mouse models. Long-term clinical intervention is required to control this complex lifestyle-related disease.",
keywords = "Non-alcoholic steatohepatitis, Oxidative stress",
author = "Akinobu Takaki and Daisuke Kawai and Kazuhide Yamamoto",
year = "2014",
month = "4",
day = "1",
language = "English",
isbn = "9781631175794",
pages = "139--176",
booktitle = "Oxidative Stress: Causes, Role in Diseases and Biological Effects",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Controlling oxidative stress in non-alcoholic steatohepatitis (NASH)

AU - Takaki, Akinobu

AU - Kawai, Daisuke

AU - Yamamoto, Kazuhide

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Non-alcoholic steatohepatitis (NASH) is a severe form of non- alcoholic fatty liver disease (NAFLD), in which most patients exhibit non-progressive non-alcoholic fatty liver (NAFL) representing simple steatosis of the liver. Multiple hits, including genetic differences, fat accumulation, insulin resistance and intestinal microbiota changes, account for the progression NASH. NAFLD is strongly associated with obesity, which induces adipokine secretion, endoplasmic reticulum (ER) and oxidative stress at the cellular level, and induces hepatic steatosis, inflammation and fibrosis. Among these factors, oxidative stress is considered a key contributor to the progression from NAFL to NASH. Although several clinical trials have shown that anti-oxidative therapy with vitamin E can effectively control the effects of hepatitis in the short term, the long-term effects remains obscure. Several trials of long-term anti-oxidant protocols aimed at treating cerebrovascular diseases or cancer development have failed to demonstrate benefits. This might be attributed to the non-selective anti-oxidant properties or excessive anti- oxidative effects of these drugs. Molecular hydrogen has recently been identified as an effective antioxidant that specifically reduces cytotoxic reactive oxygen species (ROS). Several diseases associated with oxidative stress, such as ischemia reperfusion injury of brain or heart, Parkinson's disease, post-chemotherapeutic renal injury, or transplant rejection, are responsive to hydrogen. The progress of NASH and transition of NASH to hepatocellular carcinoma can be controlled using hydrogen-rich water in mouse models. Long-term clinical intervention is required to control this complex lifestyle-related disease.

AB - Non-alcoholic steatohepatitis (NASH) is a severe form of non- alcoholic fatty liver disease (NAFLD), in which most patients exhibit non-progressive non-alcoholic fatty liver (NAFL) representing simple steatosis of the liver. Multiple hits, including genetic differences, fat accumulation, insulin resistance and intestinal microbiota changes, account for the progression NASH. NAFLD is strongly associated with obesity, which induces adipokine secretion, endoplasmic reticulum (ER) and oxidative stress at the cellular level, and induces hepatic steatosis, inflammation and fibrosis. Among these factors, oxidative stress is considered a key contributor to the progression from NAFL to NASH. Although several clinical trials have shown that anti-oxidative therapy with vitamin E can effectively control the effects of hepatitis in the short term, the long-term effects remains obscure. Several trials of long-term anti-oxidant protocols aimed at treating cerebrovascular diseases or cancer development have failed to demonstrate benefits. This might be attributed to the non-selective anti-oxidant properties or excessive anti- oxidative effects of these drugs. Molecular hydrogen has recently been identified as an effective antioxidant that specifically reduces cytotoxic reactive oxygen species (ROS). Several diseases associated with oxidative stress, such as ischemia reperfusion injury of brain or heart, Parkinson's disease, post-chemotherapeutic renal injury, or transplant rejection, are responsive to hydrogen. The progress of NASH and transition of NASH to hepatocellular carcinoma can be controlled using hydrogen-rich water in mouse models. Long-term clinical intervention is required to control this complex lifestyle-related disease.

KW - Non-alcoholic steatohepatitis

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84954624507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954624507&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84954624507

SN - 9781631175794

SN - 9781631175787

SP - 139

EP - 176

BT - Oxidative Stress: Causes, Role in Diseases and Biological Effects

PB - Nova Science Publishers, Inc.

ER -